ទំព័រដើម › មហារីកទ្រូង › កុនិចធីគត › New Haven
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកទ្រូង នៅក្នុង New Haven, CT
ការសិក្សាចំនួន 38 សម្រាប់ មហារីកទ្រូង កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ New Haven (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
A Study of PHST001 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale Cancer Center, New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale Cancer Center, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale University - Yale University School of Medicine, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale Cancer Center ( Site 0060), New Haven
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
កំពុងជ្រើសរើសដំណាក់កាល 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · ឆ្ងាយ 7 ម៉ាយ
- និង 2 ទៀត
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
កំពុងជ្រើសរើស
- Yale Cancer Center, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Trial Site, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale Cancer Center, New Haven
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Smilow Cancer Hospital at Yale New Haven, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · ឆ្ងាយ 7 ម៉ាយ
- Smilow Cancer Hospital-Derby Care Center, Derby · ឆ្ងាយ 8 ម៉ាយ
- និង 1 ទៀត
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale University Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · ឆ្ងាយ 7 ម៉ាយ
- Smilow Cancer Hospital Care center at Derby, Derby · ឆ្ងាយ 8 ម៉ាយ
- និង 1 ទៀត
Optimizing Surgical Decisions in Young Adults With Breast Cancer
កំពុងជ្រើសរើស
- Yale Cancer Center, New Haven
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Yale Cancer Center, New Haven
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · ឆ្ងាយ 7 ម៉ាយ
- Smilow Cancer Hospital - Derby, Derby · ឆ្ងាយ 8 ម៉ាយ
- និង 1 ទៀត
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · ឆ្ងាយ 5 ម៉ាយ
- និង 4 ទៀត
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
កំពុងជ្រើសរើស
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
កំពុងជ្រើសរើសដំណាក់កាល 2
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
កំពុងជ្រើសរើសដំណាក់កាល 3
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Yale University, New Haven
ការសាកល្បងសម្រាប់ មហារីកទ្រូង នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 136
- Houston, TXការសិក្សា 126
- Boston, MAការសិក្សា 112
- Nashville, TNការសិក្សា 81
- Los Angeles, CAការសិក្សា 73
- Edison, NJការសិក្សា 68
- St. Louis, MOការសិក្សា 64
- Queens, NYការសិក្សា 64
- Durham, NCការសិក្សា 64
- Chicago, ILការសិក្សា 59
- Philadelphia, PAការសិក្សា 56
- Dallas, TXការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង New Haven
- Non-Small Cell Lung Cancerការសិក្សា 41
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 33
- មហារីកដែលរីករាលដាលការសិក្សា 23
- មហារីកសួតការសិក្សា 22
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 22
- មហារីកស៊ុតការសិក្សា 21
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 20
- មហារីកតូចការសិក្សា 20
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 17
- ជំងឺប្រើប្រាស់អាល់កុលលើសកម្រិត (AUD)ការសិក្សា 17
- ការប្រើប្រាស់ថ្នាំអូព្យូអ៊ីតលើសកម្រិតការសិក្សា 17
- មហារីកតំបក់ការសិក្សា 16
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។